Timothy Hughes

2 weeks ago | nature.com | Andreas Hochhaus |Dong-Wook Kim |Jorge Cortés |Koji Sasaki |Michael J. Mauro |Timothy Hughes | +7 more

AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).

May 16, 2024 | nature.com | Jorge Cortés |Koji Sasaki |Timothy Hughes |Michael J. Mauro |Andreas Hochhaus |Michael C. Heinrich | +5 more

AbstractAsciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1T315I, which is resistant to most approved adenosine triphosphate–competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability and antileukemic activity of asciminib monotherapy 200 mg twice daily in 48 heavily pretreated patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP; data cutoff: January 6, 2021).

Sep 1, 2023 | biologicalpsychiatryjournal.com | Timothy Hughes

AbstractSchizophrenia (SCZ) has a known neurodevelopmental etiology, but limited access to human prenatal brain tissue hampers the investigation of basic disease mechanisms in early brain development. Here, we elucidate the molecular mechanisms contributing to SCZ risk in a disease-relevant model of the prenatal human brain.

May 5, 2023 | nature.com | Timothy Hughes |Nils Eiel Steen |Ingrid Melle |Srdjan Djurovic |Ole A. Andreassen |Anja Torsvik | +1 more

AbstractSchizophrenia (SCZ) and bipolar disorder (BD) share clinical characteristics, genetic susceptibility, and immune alterations. We aimed to identify differential transcriptional patterns in peripheral blood cells of patients with SCZ or BD versus healthy controls (HC). We analyzed microarray-based global gene expression data in whole blood from a cohort of SCZ (N = 329), BD (N = 203) and HC (N = 189).